In addition, patients with EGFR wild-type NSCLC are intrinsic resistance to EGFR-TIKs 8, especially for concurrent with KRAS mutation or HER2 mutation 9, 10. This evidence concerns the gene KRAS and non-small cell lung carcinoma.